Methodology of Purification of Inactivated Cell-Culture-Grown SARS-CoV-2 Using Size-Exclusion Chromatography

Anastasia A. Kovpak; Anastasia N. Piniaeva; Oleg A. Gerasimov; Irina O. Tcelykh; Mayya Y. Ermakova; Anna N. Zyrina; Dmitry V. Danilov; Yury Y. Ivin; Liubov I. Kozlovskaya; Aydar A. Ishmukhametov

doi:10.3390/vaccines10060949

Vaccines (Jun 2022)

Methodology of Purification of Inactivated Cell-Culture-Grown SARS-CoV-2 Using Size-Exclusion Chromatography

Anastasia A. Kovpak,
Anastasia N. Piniaeva,
Oleg A. Gerasimov,
Irina O. Tcelykh,
Mayya Y. Ermakova,
Anna N. Zyrina,
Dmitry V. Danilov,
Yury Y. Ivin,
Liubov I. Kozlovskaya,
Aydar A. Ishmukhametov

Affiliations

Anastasia A. Kovpak: Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
Anastasia N. Piniaeva: Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
Oleg A. Gerasimov: Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
Irina O. Tcelykh: Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
Mayya Y. Ermakova: Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
Anna N. Zyrina: Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
Dmitry V. Danilov: Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
Yury Y. Ivin: Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
Liubov I. Kozlovskaya: Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
Aydar A. Ishmukhametov: Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia

DOI: https://doi.org/10.3390/vaccines10060949
Journal volume & issue: Vol. 10, no. 6
p. 949

Abstract

Read online

Various types of COVID-19 vaccines, including adenovirus, mRNA, and inactivated ones, have been developed and approved for clinical use worldwide. Inactivated vaccines are produced using a proven technology that is widely used for the production of vaccines for the prevention and control of infectious diseases, including influenza and poliomyelitis. The development of inactivated whole-virion vaccines commonly includes several stages: the production of cellular and viral biomass in cell culture; inactivation of the virus; filtration and ultrafiltration; chromatographic purification of the viral antigen; and formulation with stabilizers and adjuvants. In this study, the suitability of four resins for Size-Exclusion Chromatography was investigated for the purification of a viral antigen for the human COVID-19 vaccine.

Published in Vaccines

ISSN: 2076-393X (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine
Website: http://www.mdpi.com/journal/vaccines

About the journal

Abstract

Keywords